Sol-Gel system has huge potentialFrom Crystal Equity Research:
"A recent capital raise has shifted the health sciences company PreveCeu-tical Medical into a higher gear with its development pipeline. The Com-pany raised CA$6.5 million (US$4.9 million) in June 2018, for support of an ambitious development pipeline focused on preventative compounds using organic and nature-identical compounds.
Highest priority on the Company’s agenda is a non-opioid pain treatment compound based on cannabinoids and administered through a proprie-tary nose-to-brain drug delivery system. Called the Sol-Gel system, it is intended to deliver a therapeutic compound to a targeted diseased site at a slow, controlled rate.
The work is being undertaken through a research and development partnership with UniQuest Pty. Ltd., the development arm of the University of Queensland in Australia. Management believes the Sol-Gel system can help make application of cannabinoids more ef-fective for pain treatment without negative side effects.
The research team at UniQuest began working May 2018, with the first supplies of medical marijuana. UniQuest took delivery of cannabis samples in early May 2018, and will undertake the ’fingerprinting’ steps in the months ahead.
Management has also begun vetting alterna-tive nasal delivery devices. The Company plans to partner with a developer that has a strong track record for regulatory approval and manufacturing excellence."